
Revance Therapeutics Shareholders Reach $2.4 Million Settlement
Investors who held Revance Therapeutics common stock during the February 2025 merger with Crown Laboratories face a December 17, 2026, court hearing regarding a proposed $2.4 million class action settlement. The agreement addresses claims for shareholders not covered by previous litigation in the Tennessee federal courts.
























